Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Abstract Background Treatment of patients with solid tumors and KRAS mutations remains disappointing. One option is the combined inhibition of pathways involved in RAF‐MEK‐ERK and PI3K‐AKT‐mTOR. Methods Patients with relapsed solid tumors were treated with escalating doses of everolimus (E) 2.5‐10.0...

Full description

Bibliographic Details
Main Authors: Lucia Nogova, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Martin L. Sos, Sebastian Michels, Rieke N. Fischer, Meike Limburg, Diana S.Y. Abdulla, Thorsten Persigehl, Carsten Kobe, Sabine Merkelbach‐Bruse, Jeremy Franklin, Heiko Backes, Roland Schnell, Dirk Behringer, Britta Kaminsky, Martina Eichstaedt, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Yingying Tian, Lisa Junge, Ahmed A. Suleiman, Sebastian Frechen, Dennis Rokitta, Dongsheng Ouyang, Uwe Fuhr, Reinhard Buettner, Jürgen Wolf
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Cancer Medicine
Subjects:
FDG‐PET
KRAS mutation
non‐small‐cell lung cancer
pharmacodynamics
pharmacokinetics
Phase‐I trial
Online Access:https://doi.org/10.1002/cam4.3131

Internet

https://doi.org/10.1002/cam4.3131

Similar Items